Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
Dapagliflozin ((2S)-1,2-propanediol hydrate) is the S-isomer of Dapagliflozin 1,2-propanediol hydrate, which is an antidiabetic drug used to treat diabetes mellitus (DM). It functions as a competitive inhibitor of sodium/glucose cotransporter 2 (SGLT2), causing glucose to be excreted into the urine. Dapagliflozin, also known as (2S)-1,2-propanediol, hydrate, attenuates renal IR injury and induces HIF1 expression.
Targets |
SGLT2
|
---|---|
ln Vitro |
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (0-10 μM; 24 hours) greatly improves the cell survival in hypoxic HK2 cells in a dose-dependent manner[2].
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (0–10 μM; 2 hours) elevates HIF1 expression and phosphorylates AMPK and EKR in hypoxic HK2 cells, but has no effect on phosphorylating AMPK and ERK in normoxic HK2 cells[2]. |
Cell Assay |
Cell Line: Hypoxic HK2 cell
Concentration: 0 μM, 1 μM, 2 μM, 5 μM, 10 μM Incubation Time: 24 hours Result: Improved the cell viability in a dose-dependent manner compared with control cells. |
References |
|
Molecular Formula |
C24H35CLO9
|
---|---|
Molecular Weight |
502.9823
|
Exact Mass |
502.2
|
CAS # |
960404-48-2
|
Related CAS # |
Dapagliflozin; 461432-26-8
|
Appearance |
Powder
|
SMILES |
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl.C[C@@H](CO)O.O
|
InChi Key |
GOADIQFWSVMMRJ-UPGAGZFNSA-N
|
InChi Code |
InChI=1S/C21H25ClO6.C3H8O2.H2O/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4;/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3;1H2/t17-,18-,19+,20-,21+;3-;/m10./s1
|
Chemical Name |
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;(2S)-propane-1,2-diol;hydrate
|
Synonyms |
Dapagliflozin ((2S)-1,2-propanediol, hydrate); BMS-512148 (2S)-1,2-propanediol, hydrate
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~198.8 mM)
H2O: ~2.4 mg/mL (~4.7 mM) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9882 mL | 9.9408 mL | 19.8815 mL | |
5 mM | 0.3976 mL | 1.9882 mL | 3.9763 mL | |
10 mM | 0.1988 mL | 0.9941 mL | 1.9882 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02981966 | Active Recruiting |
Drug: Dapagliflozin Drug: Placebo |
Diabetes Mellitus, Type 2 | The University of Texas Health Science Center at San Antonio |
May 23, 2019 | Phase 4 |
NCT01714011 | Active Recruiting |
Drug: Dapagliflozin 10mg Tab Drug: Placebo |
Chronic Kidney Diseases Bone Diseases, Metabolic |
Mansoura University | November 10, 2022 | Phase 4 |
NCT03199053 | Active Recruiting |
Drug: Dapagliflozin Drug: Saxagliptin |
Diabetes Mellitus, Type 2 | AstraZeneca | October 11, 2017 | Phase 3 |
NCT04333823 | Active Recruiting |
Drug: Dapagliflozin 5mg Drug: Placebo |
Diabetes Mellitus, Type 1 | The Hospital for Sick Children | December 11, 2020 | Phase 3 |
NCT03499704 | Active Recruiting |
Drug: Dapagliflozin Drug: Metformin |
Diabetes Mellitus, Type 2 | Celltrion Pharm, Inc. | February 11, 2020 | Phase 4 |
Administration of dapagliflozin increased UGE and reduced blood glucose levels. PLoS One . 2016 Mar 10;11(3):e0150756. td> |
Dapagliflozin acutely suppressed BAT thermogenesis by reducing sympathetic nerve activity. PLoS One . 2016 Mar 10;11(3):e0150756. td> |
Dapagliflozin enhances hepatic gluconeogenesis and glycogenolysis. PLoS One . 2016 Mar 10;11(3):e0150756. td> |
Effects of dapagliflozin on renal function (S(n = 5), sham; S + Dapa (n = 5), sham + dapagliflozin; IR(n = 7), vehicle-treated renal IR mice; IR + Dapa (n = 7), dapagliflozin-treated IR mice). PLoS One . 2016 Jul 8;11(7):e0158810. td> |
Effects of dapagliflozin on HK2 cell survival and apoptosis. PLoS One . 2016 Jul 8;11(7):e0158810. td> |
Ion currents during simulated action potentials during low glucose, high glucose, and high glucose in the presence of dapagliflozin. Sci Rep . 2016 Aug 18:6:31214. td> |